UniQure said it will seek UK approval for its Huntington’s gene therapy AMT-130, submitting a marketing application later this year following a positive meeting with UK regulators. The update comes as the company tries to regain momentum after continued uncertainty in the U.S. around FDA requirements. UniQure noted the UK submission will be based on a three-year analysis from ongoing trials across the U.S. and Europe, where investigators have reported apparent slowing of disease progression at the highest tested dose. The company also said it expects an FDA discussion in the second quarter regarding key elements of a potential Phase 3 trial design. The move is significant for investors tracking gene-therapy regulatory divergence across geographies, and it keeps AMT-130’s approval path alive for a major unmet neurodegenerative disease.